Glycosylated SV2A and SV2B Mediate the Entry of Botulinum Neurotoxin E into Neurons

被引:185
|
作者
Dong, Min [1 ,2 ]
Liu, Huisheng [1 ,2 ]
Tepp, William H. [3 ]
Johnson, Eric A. [3 ]
Janz, Roger [4 ,5 ]
Chapman, Edwin R. [1 ,2 ]
机构
[1] Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA
[2] Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA
[3] Univ Wisconsin, Dept Food Microbiol & Toxicol, Madison, WI 53706 USA
[4] Univ Texas Houston, Sch Med, WM Keck Ctr Learning & Memory, Houston, TX 77030 USA
[5] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1091/mbc.E08-07-0765
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Botulinum neurotoxin E (BoNT/E) can cause paralysis in humans and animals by blocking neurotransmitter release from presynaptic nerve terminals. How this toxin targets and enters neurons is not known. Here we identified two isoforms of the synaptic vesicle protein SV2, SV2A and SV2B, as the protein receptors for BoNT/E. BoNT/E failed to enter neurons cultured from SV2A/B knockout mice; entry was restored by expressing SV2A or SV2B, but not SV2C. Mice lacking SV2B displayed reduced sensitivity to BoNT/E. The fourth luminal domain of SV2A or SV2B alone, expressed in chimeric receptors by replacing the extracellular domain of the low-density lipoprotein receptor, can restore the binding and entry of BoNT/E into neurons lacking SV2A/B. Furthermore, we found disruption of a N-glycosylation site (N573Q) within the fourth luminal domain of SV2A rendered the mutant unable to mediate the entry of BoNT/E and also reduced the entry of BoNT/A. Finally, we demonstrate that BoNT/E failed to bind and enter ganglioside-deficient neurons; entry was rescued by loading exogenous gangliosides into neuronal membranes. Together, the data reported here demonstrate that glycosylated SV2A and SV2B act in conjunction with gangliosides to mediate the entry of BoNT/E into neurons.
引用
收藏
页码:5226 / 5237
页数:12
相关论文
共 50 条
  • [21] Effects of SV2B on proliferation, invasion and migration of human glioma cells
    Duan, Hubin
    Hao, Chunyan
    Xue, Wen
    Zheng, Juan
    Qiao, Xiaohong
    FASEB JOURNAL, 2021, 35
  • [22] SV2A and SV2C contain a unique synaptotagmin-binding site
    Schivell, AE
    Mochida, S
    Kensel-Hammes, P
    Custer, KL
    Bajjalieh, SM
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2005, 29 (01) : 56 - 64
  • [23] SV2B can regulate BACE1 localization in the hippocampus
    Miyamoto, M.
    Kuzuya, A.
    Noda, Y.
    Uemura, K.
    Asada-Utsugi, M.
    Fukusumi, Y.
    Kawachi, H.
    Ito, S.
    Takahashi, R.
    Kinoshita, A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 762 - 762
  • [24] BRIVARACETAM SV2A Ligand Antiepileptic Drug
    Bestha, D. P.
    Yang, B.
    Madaan, V.
    DRUGS OF THE FUTURE, 2010, 35 (03) : 165 - 172
  • [25] Hyperexcitability of the hippocampal neurons in the synaptic vesicle protein SV2A mutant rats
    Tokudome, Kentaro
    Okumura, Takahiro
    Shimizu, Saki
    Kunisawa, Naofumi
    Tomita, Chisato
    Kitaya, Ryosuke
    Mashimo, Tomoji
    Serikawa, Tadao
    Sasa, Masashi
    Ohno, Yukihiro
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2013, 121 : 155P - 155P
  • [26] SYNAPTIC VESICLE PROTEIN 2B (SV2B) INTERACTS TO SLIT DIAPHRAGM COMPONENT
    Miyauchi, Naoko
    Han, Gi Dong
    Suzuki, Koichi
    Karasawa, Tamaki
    Harita, Yutaka
    Koike, Hiroko
    Shimizu, Fujio
    Kawachi, Hiroshi
    NEPHROLOGY, 2005, 10 : A125 - A125
  • [27] Targeting SV2A for discovery of antiepileptic drugs
    Kaminski, Rafal M.
    Gillard, Michel
    Klitgaard, Henrik
    EPILEPSIA, 2010, 51 : 83 - 83
  • [28] SV2A missense mutation facilitates the kindling epileptogenesis
    Ohno, Yukihiro
    Mashimo, Tomoji
    Okumura, Takahiro
    Ishihara, Shizuka
    Terada, Ryo
    Shimizu, Saki
    Tokudome, Kentaro
    Chie, Tomita
    Kitaya, Ryosuke
    Tanaka, Tomoya
    Kunisawa, Naofumi
    Sasa, Masashi
    Serikawa, Tadao
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2013, 121 : 87P - 87P
  • [29] SV2A PET imaging in human neurodegenerative diseases
    Bavarsad, Mahsa Shanaki
    Grinberg, Lea T.
    FRONTIERS IN AGING NEUROSCIENCE, 2024, 16
  • [30] Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons
    Kroken, Abby R.
    Blum, Faith C.
    Zuverink, Madison
    Barbieri, Joseph T.
    INFECTION AND IMMUNITY, 2017, 85 (01)